Voglibose 0.2 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg GLIMITERIS TRIO 0.2 The combination of Voglibose, Glimepiride, and Metformin Hydrochloride is a medication regimen commonly used in the management of type 2 diabetes mellitus. This combination involves three different types of oral antidiabetic drugs, each with a distinct mechanism of action, which work together to control blood sugar levels: Voglibose (0.2 mg): Class: Alpha-glucosidase inhibitor. Mechanism of Action: Voglibose works by slowing down the breakdown and absorption of carbohydrates in the intestine. This leads to a more gradual increase in blood sugar levels following meals. Use: It's particularly useful in managing postprandial (after-meal) blood glucose levels. Glimepiride (3 mg): Class: Sulfonylurea. Mechanism of Action: Glimepiride increases insulin secretion from the beta cells of the pancreas. This helps lower blood sugar by increasing insulin levels in the body. Use: Effective in improving overall blood sugar control. Considerations: The main risk associated with sulfonylureas is hypoglycemia (low blood sugar), especially if a meal is skipped or the dose is too high. Metformin Hydrochloride (500 mg): Class: Biguanide. Mechanism of Action: Metformin works by decreasing glucose production in the liver, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Use: Often the first medication prescribed for type 2 diabetes; particularly effective in overweight and obese patients. Considerations: Can cause gastrointestinal side effects; the risk of a rare but serious condition called lactic acidosis. This combination therapy is advantageous because it addresses different aspects of diabetes management: Voglibose helps control post-meal blood sugar spikes, Glimepiride boosts insulin secretion, and Metformin improves insulin sensitivity and reduces the amount of sugar released by the liver. Patients on this medication regimen should be regularly monitored for blood sugar levels, and doses may need to be adjusted based on individual response and tolerance. It's also important for patients to maintain a balanced diet and regular exercise routine, as these are crucial components of diabetes management. Steris Healthcare Pvt. Ltd. is a Leading Pharmaceutical Company in India. Established in the year of May 2018. We have 750+ Products & 16+ Super Specialty Segments. Every week we have a new product in our portfolio. In Last 5 years we are dealing in Chronic Therapy and in 5 years we grow by 200% Annually, because we deal in high quality medicine. Steris medicine manufactures at WHO-GMP Approved Plants & We have Legal manufacturing contracts with all leading manufacturers of India. Today we have 1000+ Business Franchise Partners in PAN India. Steris's medicine supply in India's Top or Reputed Hospitals, Pharmacy, Government use or Railway use. Grow with a similar pace with the STERIS. Be first to launch like us. For further information please contact: info@sterispharma.com order now:https://www.sterisonline.com/product/glimiteris-trio-0-2-134376